The launch of SCIZYS by Lumito will be slightly delayed
As previously communicated, Lumito's ambition and plan has been to offer product for researchers use only by the end of 2022. Employees and production partners have together set the plan and worked hard and focused on fulfilling the ambition, which has been deemed fully realistic until now. Lumito therefore wishes to inform that the launch […]
Lumito publishes Quarterly Report 2, 2022
First half of the year 1 January–30 June 2022 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -13,610 (-13,444). Basic and diluted earnings per share amounted to SEK -0.09 (-0.15) Cash flow from operating activities after change in working capital amounted to KSEK -14,636 (-12,883). Cash and cash equivalents amounted […]
Successful results from a pre-study completed in collaboration with Umeå University, Sweden, shows that Lumito’s technique offers better possibilities compared with other immunohistochemical methods
A now completed pre-study, initiated at the beginning of this year in collaboration with a research group at Umeå University in Sweden led by Assistant Professor Daniel Öhlund has yielded successful results. The research group intended to identify how Lumito's UCNP (Up-Converting Nano Particles) technology could be used to improve the ability to visualise protein […]
Lumito AB publishes Quarterly Report 1, 2022
Lumito AB publishes Quarterly Report 1, 2022 Financial overview of the first quarter January 1 to March 31, 2022 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -6 430 (-6 825). Earnings per share before and after dilution amounted to SEK -0.04 (-0.08). Cash flow from operating […]
Lumito signs cooperation agreement with Optronic for 0-series production of the company’s scanner
Lumito AB and Optronic Partner pr AB have signed a cooperation agreement for the final design, industrialization and 0-series production of Lumito's first Whole Slide Imaging (WSI) scanners. The scope of the agreement is based on the delivery of 0-series production prior to Lumito's planned launch for research laboratories at the end of 2022. The […]
Year-end report 2021, Lumito AB (publ)
Financial overview 1 October – 31 December 2021 Net sales amounted to KSEK 0 (0) Result after taxes amounted to KSEK -6 855 (-5 199). Basic and diluted earnings per share amounted to SEK -0.08 (-0.06). Cash flow from operating activities after change in working capital amounted to KSEK -2 270 (-5 032). Twelve months, 1 January – 31 […]
Images of high and stable quality offer excellent assessment possibilities
Lumito’s objective is to create high-quality stainings of tissue sections and corresponding imaging. A key effort has been to achieve a repeatable and robust staining methodology that can generate imaging that is optimal for a digital, visual evaluation. These objectives have now been achieved, according to Dr. Bo Holmqvist. Bo Holmqvist (CSO, Imagene-iT AB) has […]
Strategy update. Product launch in research laboratories planned for the end of 2022
By launching a product for research laboratories, Lumito enables market access by late 2022. The Company considers that there is business potential in research laboratories, which may generate sales as of 2022. In addition, it may draw media attention to the Company's technology and deepen understanding of the opportunities offered by the technology, moving forward. […]
Lumito AB publishes Quarterly Report 3, 2021
Financial overview Third quarter, January–September 2021 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -19,517 (-10,848). Basic and diluted earnings per share amounted to SEK -0.22 (-0.15). Cash flow from operating activities after change in working capital amounted to KSEK -19,927 (-12,239). Cash and cash equivalents amounted to KSEK […]
Correction of previously published press release concerning the early publication of the quarterly report
The press release published on 18 October at 13.00 contains incorrect information, as the Quarterly Report 3 2021 has not been audited. For further information, please contact: Lumito's CEO, Mattias Lundin e-mail: ml@lumito.se phone: 076-868 45 09 Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide […]